SCHEMBL6231088

SCHEMBL6231088

Nc1ccc2sc(C(=O)N3CCOCC3)cc2c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.69
GAA P10253 2/20 0.67
HPGD P15428 4/20 0.55
ALDH1A1 P00352 4/20 0.50
RIPK1 Q13546 7/20 0.48
HRH4 Q9H3N8 1/20 0.48
CHRNA7 P36544 1/20 0.47
NPSR1 Q6W5P4 1/20 0.46
KDM4E B2RXH2 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
GLA P06280 1/20 0.46
TSHR P16473 1/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
HSD17B10 Q99714 1/20 0.46
MAPT P10636 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6232921 0.86 ALDH1A1 (0.66) L3MBTL1GAAHPGDALDH1A1RIPK1
SCHEMBL6616703 0.85 ALDH1A1 (0.51) L3MBTL1GAAHPGDALDH1A1RIPK1
SCHEMBL6234089 0.84 HRH4 (0.69) L3MBTL1GAAHPGDALDH1A1HRH4
SCHEMBL18889270 0.84 L3MBTL1 (0.69) L3MBTL1GAAHPGDALDH1A1RIPK1
SCHEMBL6253982 0.82 ALDH1A1 (0.57) L3MBTL1GAAHPGDALDH1A1HRH4
SCHEMBL6233482 0.81 GAA (1.00) L3MBTL1GAAHPGDALDH1A1KDM4E
SCHEMBL18889205 0.80 RIPK1 (0.64) L3MBTL1GAAHPGDALDH1A1RIPK1
SCHEMBL18932909 0.80 L3MBTL1 (0.63) L3MBTL1GAAHPGDALDH1A1RIPK1
SCHEMBL6254206 0.78 CHRNA7 (0.53) L3MBTL1GAAALDH1A1HRH4CHRNA7
SCHEMBL6234648 0.78 CHRNA7 (0.53) L3MBTL1GAAALDH1A1HRH4CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3176163-B1 NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT IAC IN NAT UNIV CHUNGNAM (KR) 2019-04-17 EP claimed
EP-3176163-A1 NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT The Industry & Academic Cooperation in Chungnam National University (IAC) (KR) 2017-06-07 EP claimed
US-20170152268-A1 NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT MOTHER'S PHARMACEUTICAL CO., LTD. (KR) 2017-06-01 US claimed
EP-3176163-B1 NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT IAC IN NAT UNIV CHUNGNAM (KR) 2019-04-17 EP disclosed
EP-3176163-B1 NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT IAC IN NAT UNIV CHUNGNAM (KR) 2019-04-17 EP disclosed
EP-3176163-A1 NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT The Industry & Academic Cooperation in Chungnam National University (IAC) (KR) 2017-06-07 EP disclosed
EP-3176163-A1 NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT The Industry & Academic Cooperation in Chungnam National University (IAC) (KR) 2017-06-07 EP disclosed
US-20170152268-A1 NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT MOTHER'S PHARMACEUTICAL CO., LTD. (KR) 2017-06-01 US disclosed
US-20170152268-A1 NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT MOTHER'S PHARMACEUTICAL CO., LTD. (KR) 2017-06-01 US disclosed
US-20170152268-A1 NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT MOTHER'S PHARMACEUTICAL CO., LTD. (KR) 2017-06-01 US disclosed
WO-2016017980-A1 NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT 충남대학교산학협력단 2016-02-04 WO disclosed
WO-2004092181-A9 HETEROCYCLIC MCHR1 ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2005-01-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170152268-A1 NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT RIPK1, RIPK2, RIPK3 L3MBTL1 2632/4885GAA 2754/4885HPGD 1769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.